학술논문
Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic‐Pharmacokinetic Prospective Multicenter Study.
Document Type
Article
Author
Blanco‐Dorado, Sara; Maroñas, Olalla; Latorre‐Pellicer, Ana; Rodríguez Jato, María Teresa; López‐Vizcaíno, Ana; Gómez Márquez, Aurea; Bardán García, Belén; Belles Medall, Dolores; Barbeito Castiñeiras, Gema; Pérez del Molino Bernal, María Luisa; Campos‐Toimil, Manuel; Otero Espinar, Francisco; Blanco Hortas, Andrés; Durán Piñeiro, Goretti; Zarra Ferro, Irene; Carracedo, Ángel; Lamas, María Jesús; Fernández‐Ferreiro, Anxo
Source
Subject
*DRUG interactions
*PLASMA interactions
*PROTON pump inhibitors
*LONGITUDINAL method
*CYTOCHROME P-450
*GUIDED tissue regeneration
*GLUCOCORTICOIDS
*INVASIVE candidiasis
*
*
*
*
*
*
*
Language
ISSN
0277-0008
Abstract
Background: Voriconazole, a first‐line agent for the treatment of invasive fungal infections, is mainly metabolized by cytochrome P450 (CYP) 2C19. A significant portion of patients fail to achieve therapeutic voriconazole trough concentrations, with a consequently increased risk of therapeutic failure. Objective: To show the association between subtherapeutic voriconazole concentrations and factors affecting voriconazole pharmacokinetics: CYP2C19 genotype and drug–drug interactions. Methods: Adults receiving voriconazole for antifungal treatment or prophylaxis were included in a multicenter prospective study conducted in Spain. The prevalence of subtherapeutic voriconazole troughs was analyzed in the rapid metabolizer and ultra‐rapid metabolizer patients (RMs and UMs, respectively), and compared with the rest of the patients. The relationship between voriconazole concentration, CYP2C19 phenotype, adverse events (AEs), and drug–drug interactions was also assessed. Results: In this study 78 patients were included with a wide variability in voriconazole plasma levels with only 44.8% of patients attaining trough concentrations within the therapeutic range of 1 and 5.5 µg/ml. The allele frequency of *17 variant was found to be 29.5%. Compared with patients with other phenotypes, RMs and UMs had a lower voriconazole plasma concentration (RM/UM: 1.85 ± 0.24 µg/ml vs other phenotypes: 2.36 ± 0.26 µg/ml). Adverse events were more common in patients with higher voriconazole concentrations (p<0.05). No association between voriconazole trough concentration and other factors (age, weight, route of administration, and concomitant administration of enzyme inducer, enzyme inhibitor, glucocorticoids, or proton pump inhibitors) was found. Conclusion: These results suggest the potential clinical utility of using CYP2C19 genotype‐guided voriconazole dosing to achieve concentrations in the therapeutic range in the early course of therapy. Larger studies are needed to confirm the impact of pharmacogenetics on voriconazole pharmacokinetics. [ABSTRACT FROM AUTHOR]